Cyanide ions Inhibitors
1 drugsAbout Cyanide ions
Cyanide ions are a highly toxic target due to their ability to inhibit cellular respiration by binding to cytochrome c oxidase. This disruption prevents cells from utilizing oxygen, leading to rapid tissue hypoxia and potentially death, demanding immediate therapeutic intervention.
Given the lack of genetic evidence directly linking cyanide ions to disease predisposition, drug development efforts focus on improving existing antidotes. The urgency stems from cyanide's acute toxicity, setting it apart from traditional drug development targets.
Currently, one FDA-approved drug, CYANOKIT (BTG INTL), is available to counteract cyanide poisoning. This drug is a small molecule, reflecting the focus on rapid neutralization of cyanide toxicity.
Top Cyanide ions Drugs
BTG INTL is the only company with an approved drug targeting cyanide ions.
The market is highly concentrated, presenting a barrier to entry for new companies.
Cyanide ions Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Cyanide ions, using small molecule modality.
Exploring alternative modalities like chelating agents could offer a competitive advantage.
Cyanide ions Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cyanide ions. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 1 | 3 | 0 | 25% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
| Phase 4 | 3 | 3 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Cyanide ions Drug Approval Timeline (2006 - 2006)
The first and most recent drug approval for cyanide poisoning was CYANOKIT in 2006.
The lack of recent approvals suggests a saturated market or limited innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cyanide ions. A trial counts if an approved drug acting on Cyanide ions is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.